News
Serena Williams Lost 31 Pounds on GLP-1 Drug Zepbound: What to Know
Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis legend shared the weight loss medication along with regular exercise and a healthy diet helped her lose 31 pounds.
Jameela Jamil Says She's 'Uncomfortable' With Serena Williams' Weight-Loss Drug Use
Jameela Jamil is weighing in on what makes her “uncomfortable” about Serena Williams’ admission that she is using a GLP-1 drug for weight loss. Williams shared that she is using a weight loss drug in an exclusive interview with the “Today” show on Friday, and she said she’s lost 31 pounds.
Serena Williams under fire after promoting GLP-1 weight loss medication | ChicagoNOW
Serena Williams is under fire from fans after she revealed she lost more than 30 pounds with the help of a GLP-1 medication. Some critics are saying she is reiterating the narrative that you need to take medication to be healthy and achieve an acceptable standard of beauty.
Eli Lilly and Novo Nordisk already make popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site ...
WISH-TV on MSN21m
FDA-approved semaglutide aids weight loss and health conditions
Learn about the use of GLP-1 agonists for weight loss and health improvement by celebrities like Oprah and Serena Williams.
About 12% of all U.S. adults have already tried using GLP-1 agonist drugs to control their weight, according to a survey ...
One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?
The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...
Employers and benefits advisors are facing a growing challenge: How to offer access to these high-demand, life-changing ...
Anecdotal reports describe an unusual GLP-1 side effect some are calling "Ozempic vulva," which involves sagging skin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback